Obtenga las últimas noticias sobre las acciones de Enveric Biosciences con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de ENVB

Últimas noticias sobre

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CDNA

CLIK

ENVB

FLYW

HCTI

ICCT

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

Enveric Biosciences Inc

Press Releases

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Akanda

Aspire Biopharma Holdings, Inc. - Warrant

Aspire Biopharma Hldgs

Clearmind Medicine

CNS Pharma

China Pharma Holding

Evoke Pharma

Impact BioMedical

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Lexaria Bioscience

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Nutriband

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Reviva Pharmaceuticals

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

XORTX Therapeutics

HC Wainwright & Co.

Doctor,Hand,Holding,A,Holographic,Of,Human,Brain,In,Healthcare

Biotech

Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Comments

Enveric Biosciences Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL